In order to test this hypothesis we analysed in this study polymorphisms in the RMI1, TOP3A and BLM, and their association with cancer risk in available case-control materials, namely AML/MDSs (acute myeloid leukemia and myelodysplastic syndromes), malignant melanoma, and bladder and breast cancer. Here, BLM is linked to melanoma.